Publications & Posters

KemPharm^® believes that its LAT^® Platform technology offers potential benefits to improve drug properties by developing prodrugs that are new molecules with improved attributes over FDA-approved drugs, such as enhanced bioavailability, extended duration of action, increased safety, and reduced susceptibility to abuse.

Publications

Drug Development & Delivery – March 2019

“Prodrugs for ADHD Treatments: Opportunities & Potential to Fill Unmet Medical Needs”

Pain Medicine – October 28, 2017

“Pharmacokinetics and Abuse Potential of Benzhydrocodone, a Novel Prodrug of Hydrocodone, After Intranasal Administration in Recreational Drug Users”

Pain Medicine – August 25, 2017

“Relative Bioavailability, Intranasal Abuse Potential, and Safety of Benzhydrocodone/Acetaminophen Compared with Hydrocodone Bitartrate/Acetaminophen in Recreational Drug Abusers”

Pharmacoepidemiology & Drug Safety – August 3, 2017

“Patterns of abuse and routes of administration for immediate-release hydrocodone combination products”

Poster Presentations

Children and Adults with Attention-Deficit/Hyperactiviity Disorder – November 4–6, 2021

“Serdexmethylphenidate/d-Methylphenidate Capsules for Children With ADHD: Effects on SKAMP-C Evaluated Over 13 Hours in a Randomized, Double-blind, Placebo-controlled Laboratory Classroom Study”

Psych Congress – October 29–November 1, 2021

“Steady-State Pharmacokinetics and Relative Bioavailability of Serdexmethylphenidate/d-Methylphenidate, a Treatment for Attention Deficit Hyperactivity Disorder Containing a Novel Prodrug of d-Methylphenidate”

American Academy of Child & Adolescent Psychiatry – October 18-30 2021

“Single-dose Pharmacokinetics of Serdexmethylphenidate/d-Methylphenidate Capsules in Children and Adolescents With ADHD and Healthy Adults: An Evaluation of Age and Body Weight”

American Psychiatric Nurses Association – October 13-16, 2021

“Serdexmethylphenidate/d-Methylphenidate Capsules for Children With ADHD: Effects on SKAMP-C and WREMB-R as Evaluated in a Randomized, Double-blind, Placebo-controlled Laboratory Classroom Study”

American Academy of Child and Adolescent Psychiatry – October 12-24, 2020

“Patterns of Abuse of Prescription Stimulant Products from the National Addictions Vigilance Intervention Program (NAVIPPRO): 2010-2018”

American Academy of Child and Adolescent Psychiatry – October 14-19, 2019

“Effect of Food and Alternative Dosing Methods on the Pharmacokinetics of KP415, an Investigational ADHD Product Containing the Prodrug, Serdexmethylphenidate (SDX)”

The American Professional Society of ADHD and Related Disorders – January 18-20, 2019

“Single-dose Pharmacokinetics of KP415, an Investigational Product Containing the Prodrug Serdexmethylphenidate (SDX), in Children and Adolescents with ADHD”

“Dose-Proportionality and Steady-State Pharmacokinetics of KP415, an Investigational ADHD Product Containing Serdexmethylphenidate (SDX), a Novel Prodrug of d-Methylphenidate”

“Human Abuse Potential of Oral Serdexmethylphenidate (SDX), a Novel Prodrug of d-Methylphenidate, Compared to Focalin® XR and Phentermine in Recreational Stimulant Abusers”

“Human Abuse Potential of Intranasal Serdexmethylphenidate (SDX), a Novel Prodrug of d-Methylphenidate, in Recreational Stimulant Abusers”

American College of Neuropsychopharmacology – December 9-13, 2018

“Assessment of the Intravenous Abuse Potential Of Serdexmethylphenidate (SDX), a Novel, Investigational Prodrug of D-Methylphenidate: Evidence from Nonclinical and Clinical Studies”

American Academy of Child & Adolescent Psychiatry – October 22-27, 2018

“Human Abuse Potential of Intravenous Serdexmethylphenidate (SDX), a Novel Prodrug of d-Methylphenidate, in Recreational Stimulant Abusers”

“Dose-finding Study of Abuse-Related Effects of Intranasal d-Methylphenidate in Recreational Stimulant Abusers”

American Professional Society for ADHD and Related Disorders – January 12-14, 2018

“Single- and Multiple-dose Pharmacokinetics of KP415, a Novel d-Methylphenidate Product Containing a Prodrug of d-Methylphenidate, in Healthy Volunteers ”

2017 International Conference on Opioids (ICOO) – June 11-3, 2016

“Pharmacokinetics and Abuse Potential of KP511, a Novel Prodrug of Hydromorphone, after Intranasal Administration in Recreation Drug Users”

American Academy of Pain Medicine (AAPM) Annual Meeting – March 15-19, 2017

“Oral pharmacokinetics of KP511, a prodrug of hydromorphone, relative to hydromorphone in human volunteers”

“Pharmacokinetics and Abuse Potential of Benzhydrocodone, A Novel Prodrug of Hydrocodone, After Intranasal Administration in Recreational Drug Users”

2016 International Conference on Opioids (ICOO) – June 5-7, 2016

“Pharmacokinetics and Abuse Potential of Benzhydrocodone, a Novel Prodrug of Hydrocodone, After Intranasal Administration in Recreational Drug Users”

“Relative Bioavailability, Intranasal Abuse Potential, and Safety of Benzhydrocodone/Acetaminophen, a Novel Immediate-Release Hydrocodone Prodrug Combination, Compared With Hydrocodone Bitartrate/Acetaminophen in Recreational Drug Abusers”